1,2,5,8-tetrahydroxy anthraquinone has been researched along with alizarin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Czarny, A; Frackowiak, A; Gancarz, R; Gaweł, W; Skibiński, P; Zaczyńska, E | 1 |
| Inui, K; Kanamitsu, K; Katayama, W; Kitakami, R; Mizuguchi, M; Nakagawa, S; Nakagawa, Y; Okada, T; Sawai, Y; Toyooka, N; Yokoyama, T | 1 |
1 review(s) available for 1,2,5,8-tetrahydroxy anthraquinone and alizarin
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
2 other study(ies) available for 1,2,5,8-tetrahydroxy anthraquinone and alizarin
| Article | Year |
|---|---|
Synthesis of glycoside derivatives of hydroxyanthraquinone with ability to dissolve and inhibit formation of crystals of calcium oxalate. Potential compounds in kidney stone therapy.
Topics: Animals; Anthraquinones; Calcium Oxalate; Cell Line; Glycosides; Humans; Kidney Calculi; Mice; Molecular Structure; Solubility | 2010 |
Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
Topics: Amyloid Neuropathies, Familial; Anthraquinones; Crystallography, X-Ray; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Xanthones | 2021 |